#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians treating temporomandibular disorder (TMD) patients now have preliminary clinical evidence supporting cannabis extracts as a potential therapeutic option for myofascial pain that may complement or provide an alternative to conventional treatments like NSAIDs or muscle relaxants. This finding is particularly relevant for patients who experience inadequate pain relief or adverse effects from standard therapies, as it expands the evidence base for cannabinoid use in orofacial pain management. However, clinicians should note that a single trial requires validation through larger studies before changing practice patterns, and they must navigate evolving state-level regulations and insurance coverage when discussing this option with patients.
A clinical trial demonstrated that sublingual cannabis extract administration produced significant reductions in myofascial pain among patients with temporomandibular disorder (TMD), a common chronic pain condition affecting the jaw and associated musculature. This finding expands the evidence base for cannabis as a potential therapeutic option beyond neuropathic pain conditions, where most existing research has concentrated, and suggests efficacy in musculoskeletal pain syndromes that affect a substantial patient population. The sublingual delivery method offers practical advantages including rapid onset, avoidance of smoking-related harms, and ease of dosing for patients seeking alternatives to opioids or other systemic analgesics. Clinicians treating TMD patients who have not responded adequately to conventional therapies such as physical therapy, NSAIDs, or muscle relaxants may consider discussing cannabis extracts as an option, though standardized dosing protocols and longer-term safety data remain areas for further investigation. For patients interested in cannabis for myofascial pain, clinicians should provide guidance on sublingual formulations, monitor therapeutic response and adverse effects, and ensure this approach complements rather than replaces evidence-based physical rehabilitation strategies.
“What this trial demonstrates is that we finally have rigorous evidence for something patients have been telling us for years, and that means we can now counsel our myofascial pain patients on cannabis as a legitimate therapeutic option rather than dismissing it or speaking about it in whispers.”
💊 While this trial demonstrating pain reduction with sublingual cannabis extracts in temporomandibular disorder (TMD) patients is noteworthy, clinicians should recognize that NORML’s framing may reflect advocacy interests, and the single-trial evidence base remains limited for drawing firm clinical conclusions. The heterogeneity of cannabis products, variable cannabinoid profiles, and differences between sublingual delivery and other routes create challenges in translating these findings to typical clinical practice, where standardization and reproducibility are difficult. Additionally, the lack of information about trial size, control conditions, long-term outcomes, and potential confounders such as concurrent physical therapy or other pain management strategies limits our ability to assess clinical significance. For TMD patients refractory to conventional therapies, this evidence may warrant a cautious conversation about cannabis as an option where it is legal, but clinicians should counsel patients that robust, replicated trials and longer safety data are still needed
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: